Sobi's Q4 2024 Financial Overview
Swedish Orphan Biovitrum AB (publ) (Sobi) recently unveiled its financial results for the fourth quarter of 2024, demonstrating a robust performance that capped off a successful year. The total revenue for the quarter experienced a noteworthy increase of 9 percent, with a rise of 8 percent at constant exchange rates, reaching approximately SEK 7,436 million, compared to SEK 6,844 million in the previous year.
Revenue Breakdown by Segment
Focusing on specific divisions, the haematology segment revealed impressive growth, showing a remarkable 22 percent surge at constant exchange rates, totaling SEK 4,487 million as opposed to SEK 3,640 million. This growth was significantly fueled by emerging sales for treatments such as Doptelet, which garnered SEK 1,147 million, and from the newly launched Altuvoct, contributing additionally with SEK 302 million.
On the other hand, the immunology department faced challenges, with a reported drop of 12 percent at constant exchange rates, achieving SEK 2,564 million compared to SEK 2,905 million the previous year. This decline was primarily due to reduced sales for Synagis but was partially countered by strong performance from Beyfortus and Kineret, generating SEK 1,207 million and SEK 777 million respectively.
Annual Performance Highlights
Defining the full year 2024, Sobi observed a total revenue escalation of 18 percent, amounting to SEK 26,027 million. The haematology segment continued its upward trend with a growth rate of 24 percent at constant exchange rates, whereas immunology achieved a respectable growth of 11 percent.
Furthermore, the adjusted EBITA margin showed an uptick, finalizing at 36 percent, up from 34 percent as Sobi maintains a strong operational base while considering a proposal from the board of directors to forgo a dividend payout for the year.
Looking Ahead to 2025
The outlook for 2025 appears promising, as Sobi anticipates revenue growth in the high single-digit percentage range at constant exchange rates. Additionally, the company expects the adjusted EBITA margin to stabilize within the mid-30s range of revenue.
Strategic Portfolio and Innovation
Sobi is steadily investing in its strategic portfolio, which includes various innovative medications that are transforming treatment options for patients with rare diseases. This proactive approach not only aligns with ongoing medical needs but also places Sobi in a competitive position in the biopharmaceutical landscape.
Conference Call Invitation
For those interested in delving deeper into these results, Sobi invites investors, analysts, and media representatives to participate in a conference call. This event is scheduled to happen at 14:30 CET, where participants will benefit from a comprehensive presentation along with an interactive Q&A session.
Contact Information
Sobi is dedicated to ensuring effective communication with stakeholders. For additional queries, investors are encouraged to reach out to the Sobi Investor Relations Team. Details regarding global participation can be found through their communications, highlighting their commitment to accessibility for international investors.
Frequently Asked Questions
What are the major financial achievements of Sobi in Q4 2024?
Sobi reported a 9 percent increase in total revenue for Q4 2024, totaling SEK 7,436 million.
How did Sobi's haematology and immunology segments perform?
The haematology segment grew by 22 percent, while the immunology segment saw a decline of 12 percent in Q4 2024.
What is Sobi's outlook for 2025?
Sobi projects revenue growth in the high single digits and anticipates an adjusted EBITA margin in the mid-30s percentage range.
What is included in Sobi's strategic portfolio?
The strategic portfolio encompasses several key treatments, including Doptelet, Beyfortus, and the newly launched Altuvoct, among others.
How can investors participate in Sobi's conference calls?
Investors can find the necessary dial-in details in the conference call invitation shared by Sobi on their platform.
